Home » Stocks » ADMA

ADMA Biologics Inc. (ADMA)

Stock Price: $1.74 USD 0.10 (6.10%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $1.76 +0.02 (1.15%) May 7, 7:58 PM
Market Cap 201.79M
Revenue (ttm) 42.22M
Net Income (ttm) -75.75M
Shares Out 123.05M
EPS (ttm) -0.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $1.74
Previous Close $1.64
Change ($) 0.10
Change (%) 6.10%
Day's Open 1.68
Day's Range 1.66 - 1.83
Day's Volume 5,066,706
52-Week Range 1.45 - 4.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Conference Call Scheduled for May 12, 2021 at 4:30 p.m. ET Conference Call Scheduled for May 12, 2021 at 4:30 p.m. ET

3 days ago - GlobeNewsWire

Today, ADMA stock is a big mover as the company announced a very bullish FDA approval allowing the company to scale its core product. The post ADMA Stock: The Big FDA News Boosting ADMA Biologics Today ...

1 week ago - InvestorPlace

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

Penny stocks are back in a big way; which 3 should you watch? The post Penny Stocks Are Back; Here's 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...

Other stocks mentioned: BOXL, VSTM
1 week ago - PennyStocks

The FDA has approved ADMA Biologics Inc's (NASDAQ: ADMA) expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool to manufacture Intravenous Immune Globulin (...

1 week ago - Benzinga

After a painful two months, shareholders of ADMA Biologics (NASDAQ:ADMA) may finally have something the be happy about. The downtrend in the stock that began in February has ended.

2 weeks ago - Benzinga

Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection

3 weeks ago - GlobeNewsWire

Adma Biologics (ADMA) delivered earnings and revenue surprises of -17.65% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019

1 month ago - GlobeNewsWire

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

RAMSEY, N.J. and BOCA RATON, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manuf...

2 months ago - GlobeNewsWire

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

Other stocks mentioned: AVIR, BNTX, LXRX, MRNA
2 months ago - Zacks Investment Research

Adma Biologics (ADMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

Achieved Fourth Quarter 2020 Preliminary Unaudited Total Revenues of $13.9 Million, the Highest Revenue Quarter for the Company Since Inception

3 months ago - GlobeNewsWire

ADMA Biologics: A Perfect Storm

4 months ago - Seeking Alpha

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and dev...

4 months ago - GlobeNewsWire

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and dev...

4 months ago - GlobeNewsWire

ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

ADMA Biologics recently reported its Q3 earnings with a beat on EPS and revenue. In addition, the company reported encouraging commercial progress for its IVIG products despite the COVID-19 headwinds. U...

5 months ago - Seeking Alpha

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...

5 months ago - GlobeNewsWire

ADMA Biologics' (ADMA) CEO Adam Grossman on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Adma Biologics (ADMA) delivered earnings and revenue surprises of 9.52% and 7.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Generated Total Revenues of $ 28. 3 Million for the First Nine Months of 2020 , Reflecting a 63 % Increase Over the Same Prior Year Period

6 months ago - GlobeNewsWire

Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET Conference Call Scheduled for Thursday, November 5, 2020, at 4:30 p.m. ET

6 months ago - GlobeNewsWire

On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

6 months ago - Zacks Investment Research

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufa...

6 months ago - GlobeNewsWire

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to man...

7 months ago - GlobeNewsWire

ImmunoRank Offers a Faster, Simpler, More Cost Effective Way to Identify High Titer Convalescent Plasma for Use in Both Treating COVID-19 Patients and for Creating COVID-19 Hyperimmune Globulins

8 months ago - GlobeNewsWire

RAMSEY, N.J. and BOCA RATON, Fla., Sept. 02, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to man...

8 months ago - GlobeNewsWire

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Other stocks mentioned: AZN, BNTX, CERS, LMNL, PFE, SONN
8 months ago - InvestorPlace

Investors need to pay close attention to ADMA stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

Shares of ADMA Biologics are on the move following the FDA's authorization of convalescent plasma for the treatment of COVID-19 patients.

8 months ago - The Motley Fool

Convalescent plasma holds promise for treating COVID-19, but it's still unproven.

Other stocks mentioned: EBS, KMDA
8 months ago - The Motley Fool

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those...

8 months ago - Benzinga

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...

Other stocks mentioned: CERS, GRFS, KMDA, LMNL, SONN, THMO, TTOO
8 months ago - Benzinga

The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today.

Other stocks mentioned: IBIO
8 months ago - The Motley Fool

ADMA Biologics has shown substantial progress of late, opening another plasma collection facility and growing sales 78% in H1 2020 over the prior year.

8 months ago - Seeking Alpha

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: APHA, ESTE, FLMN, QUIK
9 months ago - 24/7 Wall Street

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Adma Biologics (ADMA) delivered earnings and revenue surprises of -21.05% and -24.28%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Generated Total Revenues of $18.0 Million for the First Half of 2020, Reflecting a 78% Increase Over First Half of 2019

9 months ago - GlobeNewsWire

Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET Conference Call Scheduled for Wednesday, August 5, 2020, at 4:30 p.m. ET

9 months ago - GlobeNewsWire

Investors need to pay close attention to ADMA stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

RAMSEY, N.J. and BOCA RATON, Fla. and KNOXVILLE, Tenn., July 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to ...

10 months ago - GlobeNewsWire

ADMA Biologics: Benefit From Production Ramp

10 months ago - Seeking Alpha

RAMSEY, N.J. and BOCA RATON, Fla., June 23, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, market...

10 months ago - GlobeNewsWire

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

11 months ago - Zacks Investment Research

About ADMA

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipel... [Read more...]

Industry
Biotechnology
Founded
2004
Stock Exchange
NASDAQ
Ticker Symbol
ADMA
Full Company Profile

Financial Performance

In 2020, ADMA Biologics's revenue was $42.22 million, an increase of 43.85% compared to the previous year's $29.35 million. Losses were -$75.75 million, 56.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ADMA Biologics stock is "Buy." The 12-month stock price forecast is 8.50, which is an increase of 388.51% from the latest price.

Price Target
$8.50
(388.51% upside)
Analyst Consensus: Buy